pdufa.bio
HomePDUFA Calendar › AMGN

Amgen INC (AMGN) FDA catalysts & readout calendar

Updated ·next FDA decision on the calendar
no upcoming catalyst on file · 5 past FDA decisions

FDA decision history (5)

Dec 11, 2025✓ ApprovedFDA decisionNov 19, 2025✓ ApprovedFDA decisionOct 17, 2025✓ ApprovedFDA decisionApr 3, 2025✓ ApprovedFDA decisionJan 17, 2025✓ ApprovedFDA decision

Clinical readouts (2)

2027-07ABP 9382026-07Tezepelumab
Full PDUFA calendar →All FDA decisions →Phase readouts →
See the full 2026 PDUFA calendar →

This page aggregates AMGN's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.

AMGN run-up, measured

Computed from this stock's own daily closing prices, on the same T-120 basis as the run-up study: the baseline is the close 120 trading sessions before the eve of the decision. These are measurements of what already happened, not predictions.

AMGN's past FDA decisions (n=25)
DecisionOutcomeT-120 to eveT-120 to peak
2025-12-11APPROVAL+9.0%+19.4%
2025-11-19APPROVAL+21.3%+21.3%
2025-10-17APPROVAL+5.3%+10.1%
2025-04-03APPROVAL-3.8%+3.4%
2025-01-17APPROVAL-19.4%+0.9%
2024-06-14APPROVAL+8.5%+17.9%
2024-05-17APPROVAL+18.9%+22.7%
2023-12-26CRL+25.8%+27.0%
2023-06-21APPROVAL-13.4%+4.3%
2023-02-28CRL-3.3%+20.6%
2022-12-13APPROVAL+15.3%+21.8%
2022-07-08APPROVAL+6.8%+10.8%
Showing the 12 most recent of 25.
Median across these 25 decisions: +3.2% from T-120 to the eve, +10.8% to the peak. A median over 25 events describes this stock's past only. It is not a forecast, and the cohort figures on the run-up study are the larger statistical base.

Common questions

When is the next FDA decision or readout for Amgen INC (AMGN)?

July 2027. The next catalyst for Amgen INC is ABP 938 (readout). That date is known to the month only. Dates are taken from FDA notices, company filings or ClinicalTrials.gov, and we do not publish a specific day when the source only gives a month or a quarter.

Has Amgen INC (AMGN) had an FDA decision before?

Yes, 5 in our archive: 5 approval(s) and 0 Complete Response Letter(s). The most recent was on December 11, 2025 and was an approval. Each one has its own page with the source document and the share-price reaction we measured.

How has AMGN stock moved into its FDA decisions?

Measured from this company's own daily closing prices: Median across these 25 decisions: +3.2% from T-120 to the eve, +10.8% to the peak. These are historical measurements of what already happened, not forecasts, and we publish no price targets or probability of approval.

Where does this AMGN data come from?

FDA publications, company filings with the SEC, company press releases and ClinicalTrials.gov, with share prices measured from daily closing data. Every date and outcome links the document it came from. Where an outcome was inferred from the price reaction rather than read from a filing, the page says so on its face.